INS and polycystic ovary syndrome: Moreover, swertiamarin with 66 μM was observed to be equally potent to metformin 1 mM in PCOS-IR, but, surprisingly, swertiamarin was unable to show any effect on the candidate insulin signalling from PCOS-NIR (Fig. 2, A, B, C and D).